Physician profile
Bimal D Shah
NPI 1043363617
$1,898.11
in general payments reported to CMS, 2019-2025
12 companies · $707 in 2025
The $707 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.37 · 2020: $507 · 2021: $200 · 2022: $348 · 2023: $15.16 · 2024: $107 · 2025: $707.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $829.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ge Healthcare | $670.00 | 2020-2021 | |
| Aop Health US, LLC | $517.70 | 2025 | Rapiblyk |
| Baxter Healthcare | $311.25 | 2022 | |
| Merck Sharp & Dohme LLC | $119.87 | 2019-2025 | Bridion |
| Takeda Pharmaceuticals U.S.A., INC. | $95.55 | 2022-2025 | Eohilia, Entyvio |
| Olympus America INC. | $37.02 | 2025 | Hanarostent Esophagus Tts(Ccc), Olympus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.55 | 2020 | |
| Braintree Laboratories, INC. | $34.00 | 2024 | Suflave, Sutab |
| B. Braun Medical INC. | $21.68 | 2022 | |
| Medtronic, INC. | $18.84 | 2025 | Bis |
| Regeneron Healthcare Solutions, INC. | $18.54 | 2024 | Dupixent |
| Madrigal Pharmaceuticals | $17.11 | 2025 | Rezdiffra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bimal Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.